GSK finalises acquisition of Nuvalent

GSK has recently announced the completion of its acquisition of Nuvalent, a Boston-based clinical-stage biopharmaceutical company dedicated to building precisely targeted therapies in oncology.

The deal brings three lung cancer assets into GSK’s oncology portfolio. Zidesamtinib and neladalkib are regarded as potential best-in-class therapies based on available clinical evidence and are currently under FDA review for ROS1-positive and ALK-altered non-small cell lung cancer respectively, with target decision dates expected before the end of the year. Both have received FDA Breakthrough Therapy and Orphan Drug Designations, and if cleared for use, are anticipated to launch in 2026 with multi-blockbuster commercial potential. The acquisition also brings in NVL-330, currently in Phase I development for HER2-altered non-small cell lung cancer.

“Today’s deal completion accelerates our entry into lung cancer with zidesamtinib and neladalkib and a platform for rapid expansion with Ris-Rez, our B7-H3 targeted ADC in phase III development. There is a clear need for these medicines in defined patient populations, consistent with our approach of acquiring validated assets that aim to improve standard of care,” said Luke Miels, Chief Executive Officer, GSK.

Financial considerations

GSK completed a tender offer to acquire all outstanding shares of Nuvalent under the terms of the agreement. The total equity value of the transaction stands at approximately $10.6 billion, with GSK’s aggregate investment net of cash acquired coming in at around $9.4 billion.

---

---

Related Topics and Keywords

acquisition, GSK, Nuvalent